• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Early intensive treatment of multiple sclerosis associated with slower progression of disability

byJames EnglandandAnees Daud
February 25, 2019
in Chronic Disease, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this prospective cohort study of patients with multiple sclerosis, upfront use of highly-efficacious disease modifying therapies (DMTs) compared with moderate intensity with escalation therapy was linked with a smaller change in disability score after 5-years.

2. Use of early intensive therapy was also demonstrated to have a longer time to sustained accumulation of disability.

Evidence Rating Level: 2 (Good)       

Study Rundown: In the modern-era treatment of Multiple Sclerosis (MS) consists mainly of anti-inflammatory disease modifying therapies (DMTs). Currently the most efficacious DMTs are reserved for patients with high-risk features at diagnosis due to concerns of more associated adverse effects. The upfront use of the most efficacious DMTs (Early Intensive Therapy, EIT) has been suggested to manage the disease in its early, inflammatory phase to prevent long-term disability. The current study used data from a prospective MS cohort in order to evaluate whether a EIT strategy was more effective at slowing progression of disease-related disability than the traditional escalation therapy beginning with moderately efficacious DMTs. The study found that EIT was linked with less disability at 5 years and a longer time to sustained accumulated disability.

The main strength of the study includes its modern cohort, with prospectively collected data during a time period with modern therapy. The major limitations of the study include the moderate sample size and missing data.

Click to read the study in JAMA Neurology

Relevant Reading: Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis

RELATED REPORTS

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up

Improvements in therapeutic and managing standards associated with significant reduction in risk of persistent disability in patients with pediatric-onset multiple sclerosis

In-Depth [prospective cohort]: This study used data from a population-based cohort of patients with MS living in southeast Wales, United Kingdom. Data was collected in a prospective fashion from 1998 to 2017. Patients in the cohort who were prescribed a DMT for MS were included in the study, while those participating in a clinical trial, treated at private clinics, or had insufficient data acquisition were excluded from the study. Highly efficacious DMTs included alemtuzumab and natalizumab, while moderately efficacious DMTs included interferons, glatiramer acetate, dimethyl fumarate, fingolimod, and teriflunomide. The primary outcome was change in 5-year in Expanded Disability Status Scale (EDSS) score and the secondary outcome was time to Sustained Accumulation of Disability (SAD) based off of sustained increased EDSS scores.

The study included 592 patients, of whom 104 received early intensive therapy. The EIT group had smaller change in EDSS at 5-years (0.3 [1.5] vs 1.2 [1.5], P=0.002), and longer median time to SAD: 6.0 (3.17-9.16) years for EIT and 3.14 (2.77-4.00) years for escalation therapy (P = 0.05).

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: disease-modifying treatment (DMT)multiple sclerosis
Previous Post

Parental nonmedical prescription opioid use linked to adolescent use

Next Post

Overlapping surgery not associated with adverse patient outcomes

RelatedReports

Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

October 12, 2021
Quick Take: Safety and Efficacy of Ozanimod Versus Interferon Beta-1a in Relapsing Multiple Sclerosis (SUNBEAM)
Chronic Disease

Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up

August 17, 2021
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Improvements in therapeutic and managing standards associated with significant reduction in risk of persistent disability in patients with pediatric-onset multiple sclerosis

June 2, 2021
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Neurology

Ponesimod may be superior to teriflunomide for relapsing multiple scleorsis

April 5, 2021
Next Post
Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial

Overlapping surgery not associated with adverse patient outcomes

Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease

Genetic variants in NUDT15 associated with increased risk of thiopurine-induced myelosuppression

Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities

2 Minute Medicine Rewind February 25, 2019

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
  • #VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.